Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHF 1535 + tiotropium
- Development stage
- Unknown
- Lead developer
- Chiesi
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
CHF 1535 + tiotropium is a combination therapy investigated for the treatment of chronic obstructive pulmonary disease (COPD). CHF 1535 is an inhaled fixed-dose combination under development by Chiesi, while tiotropium is a long-acting muscarinic antagonist (LAMA) widely used in COPD management. Tiotropium works by antagonizing muscarinic acetylcholine receptors (primarily M3) in airway smooth muscle, leading to bronchodilation and improved airflow[1][6][8]. The combination aims to enhance efficacy in reducing COPD exacerbations and improving lung function compared to monotherapy. Clinical studies have evaluated this combination using pressurized metered dose inhalers (pMDI) and other delivery devices[3][5].
- Brand names
- Spiriva HandiHaler
02
Targets
ADRB2 (β2)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on CHF 1535 + tiotropium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHF 1535 + tiotropium.